More than 1 in 10 older adults were misdiagnosed with community-acquired pneumonia and nearly all were treated with a full course of antibiotics, a new study found.
The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.
Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.
Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.